Comparing the eighth and the seventh editions of the American Joint Committee on Cancer staging system and the Brigham and Women's Hospital alternative staging system for cutaneous squamous cell carcinoma: Implications for clinical practice - 13/12/18
Abstract |
Background |
The new eighth edition of the American Joint Committee on Cancer staging system (AJCC-8) incorporates changes regarding cutaneous squamous cell carcinoma (CSCC).
Objectives |
We aimed to compare the AJCC-8 staging system with the previous seventh edition of the AJCC staging system (AJCC-7) and the Brigham and Women's Hospital (BWH) alternative staging system to identify their usefulness and the utility of their risk factors in defining prognostic groups in CSCC.
Methods |
A series of 186 CSCCs of the head and neck were retrospectively collected. All 3 staging systems were compared from the standpoint of their ability to predict poor prognosis. Binary logistic regression models were built to determine which risk factors were most relevant.
Results |
Poor prognosis was mainly associated with stage T2 of the AJCC-7, with stages T2b/T3 of the BWH system, and with stage T3 of the AJCC-8. The AJCC-8 and the BWH staging systems displayed overlap with each another in predicting poor prognosis, and both were superior to the AJCC-7. The new risk factors incorporated into the AJCC-8 and the poor degree of differentiation were independently associated with poor outcome.
Limitations |
Retrospective study and few cases with bone invasion.
Conclusions |
The AJCC-8 is more distinctive, monotonous, and homogeneous than the AJCC-7 and shows some overlap with the BWH system in stratification of tumors.
Le texte complet de cet article est disponible en PDF.Key words : AJCC, American Joint Committee on Cancer, Brigham and Women's Hospital, cutaneous squamous cell carcinoma, poor degree of differentiation, prognosis, skin cancer staging
Abbreviations used : AJCC, AJCC-8, AJCC-7, BWH, CSCC, SLNB, ME
Plan
Dr Moyano-Bueno and Dr Viñolas-Cuadros contributed equally to this article. |
|
Funding sources: Dr Cañueto is partially supported by a grant (GRS 1342/A/16) from the Regional Health Office of Castile and Leon and by the program INT/M/16/17 from the Regional Health Office of Castile and Leon. Dr Pérez-Losada was partially supported by FEDER and the MICINN (grants SAF2014-56989-R and SAF2017-88854-R), the Instituto de Salud Carlos III (PIE14/00066), and the We Can Be Heroes Foundation. |
|
Conflicts of interest: None disclosed. |
Vol 80 - N° 1
P. 106 - janvier 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?